Biohaven Pharma (BHVN) Tops Q4 EPS by 28c

Biohaven Pharma (NYSE: BHVN) reported Q4 EPS of ($0.90), $0.28 better than the analyst estimate of ($1.18).

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
• Trump plans to request Supreme Court rehearing on birthright citizenship
• ISS and Glass Lewis back Aterian asset sale ahead of shareholder vote